million, to Juliet, the growth first of everyone. a XX% our $XX guidance million and million sequential second and revenue for previous good Today over quarter compares $XX.X XXXX you, That this afternoon, $XX reflects reported quarter we worldwide. the to Thank quarter.
amount through improved us to my growth. the of of what of quarter general forward, spent commercial Last and particularly time fair going areas initial assessment revenue of execution focus and that my a going were the position in, we I led
So topic do than more last today, that let's start a with bit I'll so though quarter. briefly
In my first and here understand I've sales on optimize and to Nevro, four marketing our existing months and issues focused been at structure, trying priorities. largely
that by fruit, that surprised in While of we a process will what thus responsiveness saying suggest change start change to and sales should early the from quarters initiatives organization's we're I've seeing let arise anticipate me been that bear to and improvements. far early many that this these you our pleasantly take of stages few with
product territory compensation, pricing and to general force improve and take visibility training, our messaging the process sales to beginning structure, productivity, priorities. and We're strategies force performance just stability and accountability, policies, and action sales
of scalable these Of way and designed the profitability grow pave and more over revenue course, are efficient model. time way by commercial to initiatives a to
practices that ordering had last on sales their recall, growing of through the force we them efforts most refocus trials. asked high-volume burden and of on you removed placed As to company-initiated patient we our year,
two-quarter our are really patient QX revenue. on a important future to mentioned I call, implant As trials one of predictor
this of Patient the of year. XXXX and second half trial volumes flat were of most in QX
So that to began and focus And on in field improvement. far, see been sustained. we team trials, QX, to we has, immediate thus our late improvement reengaged
procedures second were full To year-over-year quarter, permanent procedures trial context for up the implant and XX% increased by some provide XX%.
wanted to behind early metrics to regarding reported While I starting progress we're every provide some quarter, to that clarity I'm the think be that revenue we'll already these going promise quarter's not this we sharing make. number
are but these Of early these we're early course, of by one the encouraged changes. days, still quarter impact of a and doesn't trend some make
sales to remind additions you this by organization. driven to important not territory was that It's our
quarter In productive helping course. of to year fact, more refining help of this will actually into slightly We're support. the with one than territories we we at XXXX. more had reps with finished patient continues just also support be specialists This territories optimization with and fewer from post-procedure be clinical the and to end throughout sales next, process that
either. continue told give I we that a regular to last on not going metrics to you were quarter turnover basis
of trends would the importantly, consider you so, the in more unwanted, voluntary our it's portion second sales low regrettable very in or was given for low, that single was over year quarter. digits the standards. that important or organization turnover However, the the voluntary And to in know turnover U.S. historical last very we by that
team I and leadership sales and turnover by experience. guess is only feel product, our new for the expected coming and of a and the are sales most the their be but Like early and organization I supported in should prospects in reduction members us, of great led, responsiveness support they products result, by excited good into in signs pipeline, of and properly needs for direction. data think success representing consistency not growth have when the our feel addressing my
already this sure, Now front to more we have but is work visible. for on do progress
This and of qualitative last our quarter mentioned market. I the specific now is growth greater and and market will important growth company direct much to a market share way large and drivers, of work through quantitative market understanding very a opportunities inform segments, study the going market our that of will We're also forward. continue strategies
ever offer both market and than ahead have that the engagement offering the persuaded our still products assumptions be future about and terms short, I'm study in base we their the In discussing of untapped be or customer of and is share, their growth encouraged business actually been now interest of it. utilization this SCS potential therapy, future that really the won't Nevro plenty the those of by I in that market of of us we the and runway we more today, While a ahead therapies details soon. in will growth market with significant
and previously, from Nevro. laying Pellegrini part foundation were as worked Both and is team. that me helping Chief instrumental of to Resources I key with and lead Lori's in look recently And appointed organizations developing and executives; and Lori creation. Chief Niamh they We've Ciano as growth benefiting value Lori consistently have Human those evaluating and a here greater leadership Commercial Officer. forward Niamh particular to Officer, senior to at Niamh our
areas In our be particular, going of a retaining single in into our attracting, customer-facing a strategy commercial very playing also central and Niamh the I be great effort. know role commercial all our fit, and our of a they'll company. and success in coordinated will unifying mission-critical top on talent enhancing initiatives all focus on given forward on supporting
only who or time. Omnia that right well planned as To SCS can put hands the for be right most truly year. doctors position the the in multiple in even effective flexibility interested for the at deliver need we therapy team the the products those quarter discussed commercial offer their combination platform of the to different of waveforms for HFXX, later are therapies. importance product will the available, as we this Last success, launch product Omnia
launch a waveform relaunch segments to than reengage ways, to base to unique expected Omnia I'm platform. customer the offers continues FDA platform this in Omnia nothing our customer what product track much us approvals pleased launch. the We and project remain our represents of many all the with new of well. a And with quarter that the series fourth opportunity to for of will base. nearly the ago, on we Omnia report less couple opportunity multiple Nevro for a to first of received a track be weeks
of I'm to just patients a diabetic pain pleased enrollment completing our and is neuropathy, for trial, we're that to from painful or front, untreated controlled the report the evaluation population. HF often few study, patient away evaluate PDN. SENZA-PDN chronic Senza who This RCT, clinical the very XX from a randomized patients this for step in large or in of important treatment therapy Nevro's an suffer On
pain XX to one literature, peripheral X resulting the million nearly the in adults can in patients affects and moderate severe in U.S., diabetic treatment. due the currently and believe of to in half medical And approximately these suffering severe management, numbness approximately or painful hands According CMM. Diabetes seeking neuropathy, feet. we patients to neuropathic conventional pain to nerves and are also are damage from and refractory are
being alone in States. is led CMM compares these principal which very of study, in XX Erika patients XXX The United centers HF CMM Dr. at and therapy neurosurgeon XX Petersen, the to by plus investigator
market further cohort to from release expect in We the data efficacy us and define the population for first patients. addressable data SCS PDN the early primary will patient endpoint of this XXXX, in these the and this see help
in physicians and work pathways our there's market market points. of done a opportunity. of lot early think for discuss going-forward XXXX, referral course, the create meantime this development Of in be to a set this plans to in to particular new to develop position, be we We'll call
we're one studies two of PDN large is conducting.
these refractory SCS, The populations or both NSRBP. next pain, few second XXXX. NSRBP the RCTs addressable the one RCT complete believe currently greatly to market expect The is in of years. ongoing expand for the opportunities enrollment nonsurgical back from sometime for trial over We we offer to in
the this is neck label precedents of to now on successful, advancement our indication, both U.S. submission proposed in concerns. for based to to neck becomes we're FDA Australian right believe not neck our studies, If prior We with understand sure submission to indication, And included a options labeling. approval. allay our patients. Regarding our as at results pain approval required support strongly current as pain FDA and treating denied need clinical available RCT to time is evaluate existing the make as that our we're a for upper well and our and pain pain limb new and data upper has working the and reminder, in that their limb we'll which the important was regulatory better
increased its payment and X under on January for range effective payment XXXX. SCS has surgical the outpatient increases CMS X% procedures last on or centers week to Additionally, of proposed proposed existing will hospitals become rule facility system, CMS codes. the OPPS. X%, prospective issued The and proposed to payments from
therapies used CMS is authorized by this by part as outpatient for Support of economic As both in Administration settings pain evaluated directed incentives for and management Act. the the non-opioid the annual alternatives need review, for
provided non-opioid honestly with of option therapies. propose treatment patients specific of changes to CMS a benefit the SCS additional not significant related for we Our as evidence did chronic and disappointed pain team scientific any non-opioid were
the in right period comment disincentives and during XX-day For continue beyond, now, provide to for step the proven a non-opioid entirely payment a therapies input of and direction, we'll the with proposed future. eliminating is increased in the goal our
that continued a legal pleased the granted result preliminary our rather against Stimwave's well extraordinary to waveforms injunction SCS patent This side, was of as portfolio the as commercial On commitment request itself. a we of high-frequency were our for Delaware the outcome patients. intellectual strength treat our property our of protect to court use
I'll over XXXX turn that, provide who more our the full with results our now guidance. QX on financial call year So Andrew, detail and to will
